Integrative analysis of multi-omics longitudinal data to identify effective strategies for the prediction and treatment of COVID-19

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:6 publications

Grant number: 10430012010002

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2023
  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)
  • Principal Investigator

    dr VK. Kumar PhD
  • Research Location

    Netherlands
  • Lead Research Institution

    Radboud Universitair Medisch Centrum
  • Research Priority Alignment

    N/A
  • Research Category

    Epidemiological studies
  • Research Subcategory

    Disease susceptibility
  • Special Interest Tags

    N/A
  • Study Type

    Unspecified
  • Clinical Trial Details

    N/A
  • Broad Policy Alignment

    Pending
  • Age Group

    Not Applicable
  • Vulnerable Population

    Unspecified
  • Occupations of Interest

    Unspecified

Abstract

Some COVID-19 patients develop very severe respiratory symptoms, while others experience mild flu-like symptoms. Although it is clear that genetic and non-genetic factors influence the severity of the disease course, the underlying molecular mechanisms are unknown. As a result, the course of the disease for an individual cannot currently be predicted. Research and expected outcomes This project aims to gain more insight into the disease and predict its progression by using long-term measurements of multi-omics data. With the ultimate goal of developing a treatment strategy for individual patients.

6 Publications linked via Europe PMC

Last Updated:6 hours ago

View all publications at Europe PMC

Cytokine-induced memory-like responses in endothelial cells link chronic inflammation to vascular disease risk.

Cytokine-induced memory-like responses in endothelial cells link chronic inflammation to vascular disease risk

Delineating sex-specific circulating host response signatures associated with COVID-19 severity and mortality.

Dexamethasone attenuates interferon-related cytokine hyperresponsiveness in COVID-19 patients.

Analysis of inflammatory protein profiles in the circulation of COVID-19 patients identifies patients with severe disease phenotypes.

Analysis of inflammatory protein profiles in the circulation of COVID-19 patients identifies patients with severe disease phenotypes